Blueprint Medicines Corporation (BPMC) Insider Sells $381,550.68 in Stock

Blueprint Medicines Corporation (NASDAQ:BPMC) insider Kate Haviland sold 6,356 shares of the company’s stock in a transaction dated Monday, September 18th. The stock was sold at an average price of $60.03, for a total transaction of $381,550.68. Following the completion of the sale, the insider now directly owns 6,356 shares in the company, valued at approximately $381,550.68. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Kate Haviland also recently made the following trade(s):

  • On Wednesday, July 5th, Kate Haviland sold 7,265 shares of Blueprint Medicines Corporation stock. The stock was sold at an average price of $54.66, for a total transaction of $397,104.90.
  • On Wednesday, June 28th, Kate Haviland sold 6,357 shares of Blueprint Medicines Corporation stock. The stock was sold at an average price of $50.00, for a total transaction of $317,850.00.

Shares of Blueprint Medicines Corporation (BPMC) opened at 62.28 on Friday. The company’s market cap is $2.44 billion. Blueprint Medicines Corporation has a one year low of $25.08 and a one year high of $64.98. The firm’s 50-day moving average is $50.77 and its 200-day moving average is $45.84.

Blueprint Medicines Corporation (NASDAQ:BPMC) last released its earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.86) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.75) by ($0.11). Blueprint Medicines Corporation had a negative net margin of 388.91% and a negative return on equity of 45.58%. The business had revenue of $5.89 million during the quarter, compared to the consensus estimate of $5.96 million. During the same quarter in the prior year, the firm earned ($0.70) EPS. The business’s revenue was down 16.7% on a year-over-year basis. Analysts expect that Blueprint Medicines Corporation will post ($3.59) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This news story was reported by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this news story on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this news story can be accessed at https://stocknewstimes.com/2017/09/23/blueprint-medicines-corporation-bpmc-insider-sells-381550-68-in-stock.html.

A number of institutional investors have recently added to or reduced their stakes in BPMC. Wellington Management Group LLP grew its position in Blueprint Medicines Corporation by 200.4% in the first quarter. Wellington Management Group LLP now owns 3,821,584 shares of the biotechnology company’s stock valued at $152,826,000 after acquiring an additional 2,549,623 shares during the last quarter. Alliancebernstein L.P. grew its position in Blueprint Medicines Corporation by 3,543.1% in the first quarter. Alliancebernstein L.P. now owns 972,699 shares of the biotechnology company’s stock valued at $38,898,000 after acquiring an additional 945,999 shares during the last quarter. FMR LLC grew its position in Blueprint Medicines Corporation by 23.4% in the first quarter. FMR LLC now owns 4,783,754 shares of the biotechnology company’s stock valued at $191,302,000 after acquiring an additional 905,614 shares during the last quarter. BlackRock Inc. grew its position in Blueprint Medicines Corporation by 39.6% in the second quarter. BlackRock Inc. now owns 2,864,255 shares of the biotechnology company’s stock valued at $145,131,000 after acquiring an additional 811,820 shares during the last quarter. Finally, OppenheimerFunds Inc. bought a new position in Blueprint Medicines Corporation in the first quarter valued at about $25,810,000. Hedge funds and other institutional investors own 90.71% of the company’s stock.

BPMC has been the topic of a number of research analyst reports. BidaskClub lowered shares of Blueprint Medicines Corporation from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 19th. Canaccord Genuity reissued a “buy” rating and set a $56.00 price objective on shares of Blueprint Medicines Corporation in a report on Monday, September 11th. Jefferies Group LLC reissued a “buy” rating and set a $56.00 price objective on shares of Blueprint Medicines Corporation in a report on Tuesday, September 5th. Cowen and Company reissued a “buy” rating on shares of Blueprint Medicines Corporation in a report on Tuesday, June 6th. Finally, Goldman Sachs Group, Inc. (The) reissued a “buy” rating and set a $79.00 price objective (up previously from $64.00) on shares of Blueprint Medicines Corporation in a report on Wednesday. One equities research analyst has rated the stock with a sell rating and eight have issued a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $54.40.

About Blueprint Medicines Corporation

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease.

Insider Buying and Selling by Quarter for Blueprint Medicines Corporation (NASDAQ:BPMC)

Receive News & Ratings for Blueprint Medicines Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply